2022
April 28, 2022
WSJ
March 21, 2022
MedCity News
Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy
January, 10-12, 2022
Biotech Showcase
2021
December 16, 2021
Bioworld
Anheart Therapeutics raises $61M in series B for precision oncology pipeline
December 14, 2021
Endpoints News
December 14, 2021
WSJ
AnHeart Takes Aim at Rare Mutation in Lung Cancer With $61 Million Financing
December 14, 2021
Biospace
With First Patients Dosed, AnHeart Snags $61 Million for Lung Cancer Hopeful
October 30, 2021
Targeted Oncology
Study of taletrectinib for ROS1 positive NSCLC Doses First Patient
October 26, 2021
Clinical Trials Arena
AnHeart Therapeutics begins dosing in Phase II lung cancer therapy trial
October 19, 2021
CURE Today
First Patient With NTRK Fusion-Positive Tumor Treated in Phase 2 Trial of Taletrectinib
September 28, 2021
OncLive
Taletrectinib Elicits Encouraging Responses in Crizotinib-Pretreated ROS1+ NSCLC
September 27, 2021
Cancer Network
Taletrectinib May Show Promise in ROS1+ Non–Small Cell Lung Cancer
September 27, 2021
European Pharmaceutical Review
Taletrectinib displays 90.5 percent objective response rate in NSCLC
